BusinessFibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDSBy Nasdaq OMXMar 31, 2017, 11:05 AM UTC
BusinessPositive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseaseBy Nasdaq OMXMar 30, 2017, 11:02 AM UTC
BusinessPositive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseaseBy Nasdaq OMXMar 30, 2017, 11:02 AM UTC
BusinessFibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in ChinaBy Nasdaq OMXJan 30, 2017, 12:00 PM UTC
BusinessFibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016By Nasdaq OMXNov 1, 2016, 9:00 PM UTC
BusinessFibroGen Completes Enrollment in Roxadustat Phase 3 Studies in ChinaBy Nasdaq OMXOct 31, 2016, 12:01 PM UTC
BusinessFibroGen Completes Enrollment in Roxadustat Phase 3 Studies in ChinaBy Nasdaq OMXOct 31, 2016, 12:01 PM UTC
